Mirk was detected in 74.5% of ovarian cancers and overexpressed in 41% of the specimens (data not shown), and the incidence was higher than that found in both cystadenomas and non-neoplastic cysts (P<0.001 and P<0.05, respectively). Here, DYRK1B is linked to cystadenoma.